750
Participants
Start Date
June 21, 2019
Primary Completion Date
June 30, 2029
Study Completion Date
June 30, 2031
Norditropin® FlexPro®
Patients will be treated with commercially available Norditropin® FlexPro® according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Norditropin® FlexPro® has been made by the treating physician and the patient's parents/legal guardian before and independently of the decision to include the patient in this study.
Uniklinik Ulm - Dt. Zentrum für Kinder- und Jugendgesundheit (DZKJ), Ulm
Lead Sponsor
Novo Nordisk A/S
INDUSTRY